LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 68

Search options

  1. Article ; Online: Molecular characteristics of breast tumors in patients screened for germline predisposition from a population-based observational study.

    Nacer, Deborah F / Vallon-Christersson, Johan / Nordborg, Nicklas / Ehrencrona, Hans / Kvist, Anders / Borg, Åke / Staaf, Johan

    Genome medicine

    2023  Volume 15, Issue 1, Page(s) 25

    Abstract: Background: Pathogenic germline variants (PGVs) in certain genes are linked to higher lifetime risk of developing breast cancer and can influence preventive surgery decisions and therapy choices. Public health programs offer genetic screening based on ... ...

    Abstract Background: Pathogenic germline variants (PGVs) in certain genes are linked to higher lifetime risk of developing breast cancer and can influence preventive surgery decisions and therapy choices. Public health programs offer genetic screening based on criteria designed to assess personal risk and identify individuals more likely to carry PGVs, dividing patients into screened and non-screened groups. How tumor biology and clinicopathological characteristics differ between these groups is understudied and could guide refinement of screening criteria.
    Methods: Six thousand six hundred sixty breast cancer patients diagnosed in South Sweden during 2010-2018 were included with available clinicopathological and RNA sequencing data, 900 (13.5%) of which had genes screened for PGVs through routine clinical screening programs. We compared characteristics of screened patients and tumors to non-screened patients, as well as between screened patients with (n = 124) and without (n = 776) PGVs.
    Results: Broadly, breast tumors in screened patients showed features of a more aggressive disease. However, few differences related to tumor biology or patient outcome remained significant after stratification by clinical subgroups or PAM50 subtypes. Triple-negative breast cancer (TNBC), the subgroup most enriched for PGVs, showed the most differences between screening subpopulations (e.g., higher tumor proliferation in screened cases). Significant differences in PGV prevalence were found between clinical subgroups/molecular subtypes, e.g., TNBC cases were enriched for BRCA1 PGVs. In general, clinicopathological differences between screened and non-screened patients mimicked those between patients with and without PGVs, e.g., younger age at diagnosis for positive cases. However, differences in tumor biology/microenvironment such as immune cell composition were additionally seen within PGV carriers/non-carriers in ER + /HER2 - cases, but not between screening subpopulations in this subgroup.
    Conclusions: Characterization of molecular tumor features in patients clinically screened and not screened for PGVs represents a relevant read-out of guideline criteria. The general lack of molecular differences between screened/non-screened patients after stratification by relevant breast cancer subsets questions the ability to improve the identification of screening candidates based on currently used patient and tumor characteristics, pointing us towards universal screening. Nevertheless, while that is not attained, molecular differences identified between PGV carriers/non-carriers suggest the possibility of further refining patient selection within certain patient subsets using RNA-seq through, e.g., gene signatures.
    Trial registration: The Sweden Cancerome Analysis Network - Breast (SCAN-B) was prospectively registered at ClinicalTrials.gov under the identifier NCT02306096.
    MeSH term(s) Humans ; Female ; Triple Negative Breast Neoplasms/diagnosis ; Triple Negative Breast Neoplasms/genetics ; Triple Negative Breast Neoplasms/pathology ; Breast Neoplasms/diagnosis ; Breast Neoplasms/genetics ; Genetic Testing ; Germ-Line Mutation ; Genetic Predisposition to Disease ; Germ Cells ; Tumor Microenvironment
    Language English
    Publishing date 2023-04-14
    Publishing country England
    Document type Observational Study ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2484394-5
    ISSN 1756-994X ; 1756-994X
    ISSN (online) 1756-994X
    ISSN 1756-994X
    DOI 10.1186/s13073-023-01177-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Intra-Patient Evolution of HIV-2 Molecular Properties.

    Palm, Angelica A / Esbjörnsson, Joakim / Kvist, Anders / Månsson, Fredrik / Biague, Antonio / Norrgren, Hans / Jansson, Marianne / Medstrand, Patrik

    Viruses

    2022  Volume 14, Issue 11

    Abstract: Limited data are available on the pathogenesis of HIV-2, and the evolution of Env molecular properties during disease progression is not fully elucidated. We investigated the intra-patient evolution of molecular properties of HIV-2 Env regions (V1-C3) ... ...

    Abstract Limited data are available on the pathogenesis of HIV-2, and the evolution of Env molecular properties during disease progression is not fully elucidated. We investigated the intra-patient evolution of molecular properties of HIV-2 Env regions (V1-C3) during the asymptomatic, treatment-naïve phase of the infection in 16 study participants, stratified into faster or slower progressors. Most notably, the rate of change in the number of potential N-linked glycosylation sites (PNGS) within the Env (V1-C3) regions differed between progressor groups. With declining CD4
    MeSH term(s) Humans ; HIV-2/genetics ; HIV-1/genetics ; HIV Seropositivity ; Glycosylation ; Disease Progression ; HIV Infections ; Evolution, Molecular
    Language English
    Publishing date 2022-11-04
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2516098-9
    ISSN 1999-4915 ; 1999-4915
    ISSN (online) 1999-4915
    ISSN 1999-4915
    DOI 10.3390/v14112447
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Author Correction: Validation of the BOADICEA model for predicting the likelihood of carrying pathogenic variants in eight breast and ovarian cancer susceptibility genes.

    Møller, Nanna Bæk / Boonen, Desirée Sofie / Feldner, Elisabeth Simone / Hao, Qin / Larsen, Martin / Lænkholm, Anne-Vibeke / Borg, Åke / Kvist, Anders / Törngren, Therese / Jensen, Uffe Birk / Boonen, Susanne Eriksen / Thomassen, Mads / Terkelsen, Thorkild

    Scientific reports

    2023  Volume 13, Issue 1, Page(s) 15294

    Language English
    Publishing date 2023-09-15
    Publishing country England
    Document type Published Erratum
    ZDB-ID 2615211-3
    ISSN 2045-2322 ; 2045-2322
    ISSN (online) 2045-2322
    ISSN 2045-2322
    DOI 10.1038/s41598-023-42606-z
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Validation of the BOADICEA model for predicting the likelihood of carrying pathogenic variants in eight breast and ovarian cancer susceptibility genes.

    Møller, Nanna Bæk / Boonen, Desirée Sofie / Feldner, Elisabeth Simone / Hao, Qin / Larsen, Martin / Lænkholm, Anne-Vibeke / Borg, Åke / Kvist, Anders / Törngren, Therese / Jensen, Uffe Birk / Boonen, Susanne Eriksen / Thomassen, Mads / Terkelsen, Thorkild

    Scientific reports

    2023  Volume 13, Issue 1, Page(s) 8536

    Abstract: BOADICEA is a comprehensive risk prediction model for breast and/or ovarian cancer (BC/OC) and for carrying pathogenic variants (PVs) in cancer susceptibility genes. In addition to BRCA1 and BRCA2, BOADICEA version 6 includes PALB2, CHEK2, ATM, BARD1, ... ...

    Abstract BOADICEA is a comprehensive risk prediction model for breast and/or ovarian cancer (BC/OC) and for carrying pathogenic variants (PVs) in cancer susceptibility genes. In addition to BRCA1 and BRCA2, BOADICEA version 6 includes PALB2, CHEK2, ATM, BARD1, RAD51C and RAD51D. To validate its predictions for these genes, we conducted a retrospective study including 2033 individuals counselled at clinical genetics departments in Denmark. All counselees underwent comprehensive genetic testing by next generation sequencing on suspicion of hereditary susceptibility to BC/OC. Likelihoods of PVs were predicted from information about diagnosis, family history and tumour pathology. Calibration was examined using the observed-to-expected ratio (O/E) and discrimination using the area under the receiver operating characteristics curve (AUC). The O/E was 1.11 (95% CI 0.97-1.26) for all genes combined. At sub-categories of predicted likelihood, the model performed well with limited misestimation at the extremes of predicted likelihood. Discrimination was acceptable with an AUC of 0.70 (95% CI 0.66-0.74), although discrimination was better for BRCA1 and BRCA2 than for the other genes in the model. This suggests that BOADICEA remains a valid decision-making aid for determining which individuals to offer comprehensive genetic testing for hereditary susceptibility to BC/OC despite suboptimal calibration for individual genes in this population.
    MeSH term(s) Humans ; Female ; Retrospective Studies ; Genetic Testing ; Genes, BRCA2 ; Genetic Predisposition to Disease ; Breast Neoplasms/diagnosis ; Ovarian Neoplasms/genetics ; Ovarian Neoplasms/epidemiology
    Language English
    Publishing date 2023-05-26
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2615211-3
    ISSN 2045-2322 ; 2045-2322
    ISSN (online) 2045-2322
    ISSN 2045-2322
    DOI 10.1038/s41598-023-35755-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer.

    Öfverholm, Anna / Törngren, Therese / Rosén, Anna / Arver, Brita / Einbeigi, Zakaria / Haraldsson, Karin / Ståhlbom, Anne Kinhult / Kuchinskaya, Ekaterina / Lindblom, Annika / Melin, Beatrice / Paulsson-Karlsson, Ylva / Stenmark-Askmalm, Marie / Tham, Emma / von Wachenfeldt, Anna / Kvist, Anders / Borg, Åke / Ehrencrona, Hans

    BMC cancer

    2023  Volume 23, Issue 1, Page(s) 738

    Abstract: Background: Genetic screening for pathogenic variants (PVs) in cancer predisposition genes can affect treatment strategies, risk prediction and preventive measures for patients and families. For decades, hereditary breast and ovarian cancer (HBOC) has ... ...

    Abstract Background: Genetic screening for pathogenic variants (PVs) in cancer predisposition genes can affect treatment strategies, risk prediction and preventive measures for patients and families. For decades, hereditary breast and ovarian cancer (HBOC) has been attributed to PVs in the genes BRCA1 and BRCA2, and more recently other rare alleles have been firmly established as associated with a high or moderate increased risk of developing breast and/or ovarian cancer. Here, we assess the genetic variation and tumor characteristics in a large cohort of women with suspected HBOC in a clinical oncogenetic setting.
    Methods: Women with suspected HBOC referred from all oncogenetic clinics in Sweden over a six-year inclusion period were screened for PVs in 13 clinically relevant genes. The genetic outcome was compared with tumor characteristics and other clinical data collected from national cancer registries and hospital records.
    Results: In 4622 women with breast and/or ovarian cancer the overall diagnostic yield (the proportion of women carrying at least one PV) was 16.6%. BRCA1/2 PVs were found in 8.9% of women (BRCA1 5.95% and BRCA2 2.94%) and PVs in the other breast and ovarian cancer predisposition genes in 8.2%: ATM (1.58%), BARD1 (0.45%), BRIP1 (0.43%), CDH1 (0.11%), CHEK2 (3.46%), PALB2 (0.84%), PTEN (0.02%), RAD51C (0.54%), RAD51D (0.15%), STK11 (0) and TP53 (0.56%). Thus, inclusion of the 11 genes in addition to BRCA1/2 increased diagnostic yield by 7.7%. The yield was, as expected, significantly higher in certain subgroups such as younger patients, medullary breast cancer, higher Nottingham Histologic Grade, ER-negative breast cancer, triple-negative breast cancer and high grade serous ovarian cancer. Age and tumor subtype distributions differed substantially depending on genetic finding.
    Conclusions: This study contributes to understanding the clinical and genetic landscape of breast and ovarian cancer susceptibility. Extending clinical genetic screening from BRCA1 and BRCA2 to 13 established cancer predisposition genes almost doubles the diagnostic yield, which has implications for genetic counseling and clinical guidelines. The very low yield in the syndrome genes CDH1, PTEN and STK11 questions the usefulness of including these genes on routine gene panels.
    MeSH term(s) Humans ; Female ; BRCA1 Protein/genetics ; BRCA2 Protein/genetics ; Genetic Predisposition to Disease ; Breast Neoplasms/diagnosis ; Breast Neoplasms/genetics ; Genetic Testing ; Ovarian Neoplasms/diagnosis ; Ovarian Neoplasms/genetics ; Protein Serine-Threonine Kinases/genetics ; Triple Negative Breast Neoplasms/genetics ; Hereditary Breast and Ovarian Cancer Syndrome/diagnosis ; Hereditary Breast and Ovarian Cancer Syndrome/genetics ; Germ-Line Mutation
    Chemical Substances BRCA1 protein, human ; BRCA1 Protein ; BRCA2 protein, human ; BRCA2 Protein ; Protein Serine-Threonine Kinases (EC 2.7.11.1)
    Language English
    Publishing date 2023-08-10
    Publishing country England
    Document type Journal Article
    ZDB-ID 2041352-X
    ISSN 1471-2407 ; 1471-2407
    ISSN (online) 1471-2407
    ISSN 1471-2407
    DOI 10.1186/s12885-023-11229-y
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Prevalence of germline pathogenic variants in 22 cancer susceptibility genes in Swedish pediatric cancer patients.

    von Stedingk, Kristoffer / Stjernfelt, Karl-Johan / Kvist, Anders / Wahlström, Cecilia / Kristoffersson, Ulf / Stenmark-Askmalm, Marie / Wiebe, Thomas / Hjorth, Lars / Koster, Jan / Olsson, Håkan / Øra, Ingrid

    Scientific reports

    2021  Volume 11, Issue 1, Page(s) 5307

    Abstract: Up to 10% of pediatric cancer patients harbor pathogenic germline variants in one or more cancer susceptibility genes. A recent study from the US reported pathogenic variants in 22 out of 60 analyzed autosomal dominant cancer susceptibility genes, ... ...

    Abstract Up to 10% of pediatric cancer patients harbor pathogenic germline variants in one or more cancer susceptibility genes. A recent study from the US reported pathogenic variants in 22 out of 60 analyzed autosomal dominant cancer susceptibility genes, implicating 8.5% of pediatric cancer patients. Here we aimed to assess the prevalence of germline pathogenic variants in these 22 genes in a population-based Swedish cohort and to compare the results to those described in other populations. We found pathogenic variants in 10 of the 22 genes covering 3.8% of these patients. The prevalence of TP53 mutations was significantly lower than described in previous studies, which can largely be attributed to differences in tumor diagnosis distributions across the three cohorts. Matched family history for relatives allowed assessment of familial cancer incidence, however, no significant difference in cancer incidence was found in families of children carrying pathogenic variants compared to those who did not.
    MeSH term(s) Biomarkers, Tumor/genetics ; Child ; Cohort Studies ; Genetic Predisposition to Disease ; Germ-Line Mutation ; Humans ; Neoplasms/epidemiology ; Neoplasms/genetics ; Prevalence ; Sweden/epidemiology
    Chemical Substances Biomarkers, Tumor
    Language English
    Publishing date 2021-03-05
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2615211-3
    ISSN 2045-2322 ; 2045-2322
    ISSN (online) 2045-2322
    ISSN 2045-2322
    DOI 10.1038/s41598-021-84502-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: Precision Oncology of High-Grade Ovarian Cancer Defined through Targeted Sequencing.

    Wessman, Sandra / Fuentes, Beatriz Bohorquez / Törngren, Therese / Kvist, Anders / Kokaraki, Georgia / Menkens, Hanna / Hjerpe, Elisabet / Hugo, Ythalo / Petta, Tirzah Braz / Borg, Åke / Carlson, Joseph W

    Cancers

    2021  Volume 13, Issue 20

    Abstract: Background: We examined whether molecular characterization of high-grade epithelial ovarian cancer can inform the diagnosis and/or identify potential actionable targets.: Methods: All of the consecutively sequenced high-grade ovarian tumours with ... ...

    Abstract Background: We examined whether molecular characterization of high-grade epithelial ovarian cancer can inform the diagnosis and/or identify potential actionable targets.
    Methods: All of the consecutively sequenced high-grade ovarian tumours with consent between 2014 until 2019 were included. A total of 274 tumours underwent next generation sequencing using a targeted panel.
    Results: Patients with high-grade ovarian epithelial cancer were consented to prospective molecular characterization. Clinical information was extracted from their medical record. Tumour DNA was subjected to sequencing, and selected patients received PARP inhibitor therapy.
    Conclusions: Tumours from 274 women were sequenced, including high-grade serous carcinoma (
    Language English
    Publishing date 2021-10-19
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers13205240
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Author Correction: Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma.

    Lauss, Martin / Donia, Marco / Harbst, Katja / Andersen, Rikke / Mitra, Shamik / Rosengren, Frida / Salim, Maryem / Vallon-Christersson, Johan / Törngren, Therese / Kvist, Anders / Ringnér, Markus / Svane, Inge Marie / Jönsson, Göran

    Nature communications

    2020  Volume 11, Issue 1, Page(s) 1714

    Abstract: An amendment to this paper has been published and can be accessed via a link at the top of the paper. ...

    Abstract An amendment to this paper has been published and can be accessed via a link at the top of the paper.
    Language English
    Publishing date 2020-04-01
    Publishing country England
    Document type Published Erratum
    ZDB-ID 2553671-0
    ISSN 2041-1723 ; 2041-1723
    ISSN (online) 2041-1723
    ISSN 2041-1723
    DOI 10.1038/s41467-020-15531-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Multiplex profiling of serum proteins in solution using barcoded antibody fragments and next generation sequencing.

    Brofelth, Mattias / Ekstrand, Anna Isinger / Gour, Shashank / Jansson, Ronnie / Hedhammar, My / Elleby, Björn / Kvist, Anders / Wingren, Christer / Axelsson, Ulrika / Borrebaeck, Carl A K

    Communications biology

    2020  Volume 3, Issue 1, Page(s) 339

    Abstract: The composition of serum proteins is reflecting the current health status and can, with the right tools, be used to detect early signs of disease, such as an emerging cancer. An earlier diagnosis of cancer would greatly increase the chance of an improved ...

    Abstract The composition of serum proteins is reflecting the current health status and can, with the right tools, be used to detect early signs of disease, such as an emerging cancer. An earlier diagnosis of cancer would greatly increase the chance of an improved outcome for the patients. However, there is still an unmet need for proficient tools to decipher the information in the blood proteome, which calls for further technological development. Here, we present a proof-of-concept study that demonstrates an alternative approach for multiplexed protein profiling of serum samples in solution, using DNA barcoded scFv antibody fragments and next generation sequencing. The outcome shows high accuracy when discriminating samples derived from pancreatic cancer patients and healthy controls and represents a scalable alternative for serum analysis.
    MeSH term(s) Biomarkers, Tumor/blood ; Blood Proteins/analysis ; Blood Proteins/immunology ; Blood Proteins/metabolism ; Carcinoma, Pancreatic Ductal/blood ; Carcinoma, Pancreatic Ductal/pathology ; Case-Control Studies ; Computational Biology ; High-Throughput Nucleotide Sequencing ; Humans ; Pancreatic Neoplasms/blood ; Pancreatic Neoplasms/pathology ; Proteome/analysis ; Proteome/immunology ; Proteome/metabolism ; Single-Chain Antibodies/genetics ; Single-Chain Antibodies/immunology
    Chemical Substances Biomarkers, Tumor ; Blood Proteins ; Proteome ; Single-Chain Antibodies
    Language English
    Publishing date 2020-07-03
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 2399-3642
    ISSN (online) 2399-3642
    DOI 10.1038/s42003-020-1068-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: BRCAsearch: written pre-test information and BRCA1/2 germline mutation testing in unselected patients with newly diagnosed breast cancer.

    Nilsson, Martin P / Törngren, Therese / Henriksson, Karin / Kristoffersson, Ulf / Kvist, Anders / Silfverberg, Barbro / Borg, Åke / Loman, Niklas

    Breast cancer research and treatment

    2017  Volume 168, Issue 1, Page(s) 117–126

    Abstract: Purpose: To evaluate a simplified method of pre-test information and germline BRCA1/2 mutation testing.: Methods: In a prospective, single-arm study, comprehensive BRCA1/2 testing was offered to unselected patients with newly diagnosed breast cancer ... ...

    Abstract Purpose: To evaluate a simplified method of pre-test information and germline BRCA1/2 mutation testing.
    Methods: In a prospective, single-arm study, comprehensive BRCA1/2 testing was offered to unselected patients with newly diagnosed breast cancer at three hospitals in south Sweden (BRCAsearch, ClinicalTrials.gov Identifier: NCT02557776). Pre-test information was provided by a standardized invitation letter, but the patients could contact a genetic counselor for telephone genetic counseling if they felt a need for that. Noncarriers were informed about the test result through a letter. Mutation carriers were contacted and offered an appointment for in-person post-test genetic counseling.
    Results: During the period Feb 2, 2015-Aug 26, 2016, eight hundred and eighteen patients were invited to participate in the study. Through Jan 31, 2017, five hundred and forty-two (66.2%) of them consented to analysis of BRCA1 and BRCA2. Eleven pathogenic mutations were found (BRCA1, n = 2; BRCA2, n = 9), corresponding to a mutation prevalence of 2.0%. Six out of 11 fulfilled the Swedish BRCA testing criteria, and 9 out of 11 fulfilled the NCCN testing criteria. None of the BRCA-associated tumors were of the luminal A-like subtype. Very few patients contacted us for telephone genetic counseling or practical questions, suggesting that a majority felt that the written pre-test information was sufficient for them to make a decision on testing.
    Conclusions: Streamlining the process of pre-test information, genetic testing, and delivery of test results was feasible and was associated with an uptake of genetic testing in 2/3 of the breast cancer patients.
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; BRCA1 Protein/genetics ; BRCA2 Protein/genetics ; Breast Neoplasms/diagnosis ; Breast Neoplasms/genetics ; Feasibility Studies ; Female ; Genetic Counseling/methods ; Genetic Counseling/statistics & numerical data ; Genetic Predisposition to Disease ; Genetic Testing/methods ; Genetic Testing/statistics & numerical data ; Germ-Line Mutation ; Humans ; Middle Aged ; Patient Acceptance of Health Care/statistics & numerical data ; Prospective Studies ; Sweden
    Chemical Substances BRCA1 Protein ; BRCA1 protein, human ; BRCA2 Protein ; BRCA2 protein, human
    Language English
    Publishing date 2017-11-21
    Publishing country Netherlands
    Document type Clinical Trial ; Journal Article ; Multicenter Study
    ZDB-ID 604563-7
    ISSN 1573-7217 ; 0167-6806
    ISSN (online) 1573-7217
    ISSN 0167-6806
    DOI 10.1007/s10549-017-4584-y
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top